Sign in Subscribe
Algorithms

Diabetes Pipeline Insight 2025: Comprehensive Analysis of 200+ Companies and 200+ Therapies

Strategic Insights

— 2 min read

Diabetes is a chronic metabolic disorder characterized by high blood sugar levels, resulting from the body's inability to produce enough insulin or use it effectively. The disease comes in various forms, including Type 1 and Type 2 diabetes, gestational diabetes, and less common forms like Maturity-Onset Diabetes of the Young (MODY) and Latent Autoimmune Diabetes in Adults (LADA). Symptoms vary by type and severity, but typically include excessive thirst, frequent urination, increased hunger, unintended weight loss, fatigue, and blurred vision due to unstable glucose levels. Type 2 diabetes may also involve slow-healing wounds, recurrent infections, and numbness or tingling in the extremities, signs of possible nerve damage.

Key Takeaways:

  • DelveInsight's Diabetes pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Diabetes treatment.
  • In November 2025, GIOSTAR announced that it received FDA clearance for its Investigational New Drug (IND) application to begin a Phase 2 clinical trial for the development of a targeted stem cell therapy for Type II Diabetes.
  • In January 2025, Glenmark Pharmaceuticals Ltd., a global research-driven pharmaceutical company, introduced a biosimilar of the widely used anti-diabetic drug Liraglutide in India for the first time.
  • Key Diabetes companies such as vTv Therapeutics, Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical, and others are evaluating new drugs for Diabetes to improve the treatment landscape.
  • Promising Diabetes pipeline therapies in various stages of development include Cadisegliatin, LY-3209590, THDB0206, CPL207280, XW014, KN056, and others.
  • DelveInsight's report provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Diabetes Therapeutics Market.

Statistics:

  • Over 200 companies are involved in developing diabetes treatments, with vTv Therapeutics, Eli Lilly and Company, and Tonghua Dongbao Pharmaceutical having drug candidates that have progressed to Phase III clinical trials.
  • The report covers 180+ active players working to develop 200+ pipeline therapies for Diabetes treatment.
  • Promising Diabetes pipeline therapies in various stages of development include Cadisegliatin, LY-3209590, THDB0206, CPL207280, XW014, KN056, and others.

Sources:

  • DelveInsight's, "Diabetes - Pipeline Insight, 2025" report
  • GIOSTAR, FDA clearance for Investigational New Drug (IND) application
  • Glenmark Pharmaceuticals Ltd., introduction of a biosimilar of Liraglutide in India
  • vTv Therapeutics, Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical, and others' pipeline development
  • Cadisegliatin, LY-3209590, THDB0206, CPL207280, XW014, KN056, and others' pipeline development
  • Diabetes Therapeutic Assessment Table of Content (DelveInsight)

Read more